Identifiants & Marche
Ticker
HROWL
ISIN
US4158582084
CIK
0001360214
Bourse
NASDAQ
Devise
USD
Entreprise
Pays
US
Siege
N/A
Fondee
N/A
Description
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.